Syngulon, a biotech company based in Belgium, has announced a new licensing agreement with Elanco, a global leader in animal health solutions. This partnership grants Elanco worldwide rights to use Syngulon’s innovative bacteriocin-based microbial selection technologies. These are cutting-edge tools that are set to transform how animal health products are developed and made.
These technologies improve the stability and efficiency of microbes used in fermentation processes. That means better, more sustainable ways to produce vital proteins and DNA, all without relying on antibiotics. It’s a big step forward for responsible biotech innovation, and aligns perfectly with Elanco’s mission to deliver impactful solutions that meet real needs.
Guy Hélin, CEO of Syngulon, shared his excitement: “Partnering with Elanco is a fantastic opportunity to expand the reach of our fermentation technologies. This agreement shows confidence in our platform and fuels our drive to create sustainable, innovative solutions for the industry.”
Mayur Patel, Elanco’s Vice President of Global R&D, echoed this enthusiasm: “Syngulon’s technology is a real game-changer. It supports our commitment to delivering high-quality, responsible innovations that improve animal health worldwide. We’re thrilled to collaborate on this journey.”
Both companies emphasized their shared dedication to responsible science and next-generation animal health products. This collaboration marks a promising step toward more sustainable, antibiotic-free manufacturing that benefits animals, farmers, and the environment alike.
Together, Syngulon and Elanco are forging a path toward a healthier, more sustainable future in animal health innovations.
The post Elanco partners with Syngulon to advance sustainable animal products appeared first on World Bio Market Insights.
